Inspire Medical Systems’s (NYSE:INSP) Q4: Beats On Revenue
Medical technology company Inspire Medical Systems (NYSE:INSP) reported Q4 CY2024 results , with sales up 24.5% year on year to $239.7 million. The company expects the full year’s revenue to be around $947.
Inspire Medical Systems, Inc. (NYSE:INSP) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript February 10, 2025 Inspire Medical Systems, Inc. beats earnings expectations. Reported EPS is $1.15, expectations were $0.74. Operator: Good afternoon. My name is Dilem [ph] and I’ll be your conference operator today.
Inspire Medical Systems, Inc. Announces Fourth Quarter and Full Year 2024 Financial Results and Updates 2025 Outlook
MINNEAPOLIS, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today reported financial results for the quarter and year ended December 31, 2024.
Inspire Medical Systems, Inc. (INSP) Q4 2024 Earnings Call Transcript
Inspire Medical Systems, Inc. ( NYSE: INSP) Q4 2024 Earnings Conference Call February 10, 2025 5:00 PM ET Ezgi Yagci - Vice President of Investor Relations Tim Herbert - President & Chief Executive Officer Rick Buchholz - Chief Financial Officer
Inspire Medical's Earnings Surge in Q4
Inspire Medical Systems ( INSP -0.64%), known for its innovative devices that use neurostimulation to treat sleep apnea, announced impressive fourth-quarter results on Feb. 10. Earnings per share (EPS) came in at $1.
Truist Financial Sticks to Their Buy Rating for Inspire Medical Systems (INSP)
In a report released today, Richard Newitter from Truist Financial maintained a Buy rating on Inspire Medical Systems (INSP – Research Report).
Inspire Medical Systems targets $940M-$955M revenue in 2025 with Inspire V launch
Q4 2024 Management View CEO Tim Herbert highlighted milestones in 2024, including surpassing 90,000 patients treated with Inspire therapy, FDA approval of the Inspire V neurostimulator, and achieving full-body MRI compatibility in the European Union.
Inspire Medical Systems Reports Strong Growth in 2024
Inspire Medical ( ($INSP) ) has released its Q4 earnings. Here is a breakdown of the information Inspire Medical presented to its investors.
Inspire Medical reports Q4 EPS $1.15, consensus 72c
Reports Q4 revenue $239.72M, consensus $237.41M. “We are thrilled with our strong performance in the fourth quarter, growing revenue 25%
MedTech Dive1d
Inspire Medical reveals DOJ civil investigation
CEO Tim Herbert told investors the company received a civil investigative demand from the Department of Justice in January ...
MassDevice1d
Inspire Medical faces DOJ investigation
Inspire Medical shares dipped — but have since mostly recovered — following news of a government investigation following Q4 ...
Analysts Offer Insights on Healthcare Companies: Inspire Medical Systems (INSP), Vertex Pharmaceuticals (VRTX) and Incyte (INCY)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Inspire Medical Systems (INSP – Research ...
Inspire Medical Receives Investigative Demand from Justice Department
Inspire Medical Systems said it is cooperating with U.S. Justice Department probe of allegations into allegations of false claims related to its Inspire system apnea implant. Shares fall 5.5% to $171 ...
Nasdaq1mon
Inspire Medical Systems Reports Strong Preliminary Revenue Growth for Q4 and Full Year 2024, Provides 2025 Guidance
Inspire Medical Systems, Inc. announced preliminary fourth quarter and full year 2024 financial results, revealing anticipated revenues of approximately $239.5 million to $239.7 million for Q4 ...
Yahoo Finance3d
Inspire Medical Systems (INSP) To Report Earnings Tomorrow: Here Is What To Expect
Medical technology company Inspire Medical Systems (NYSE:INSP) will be reporting results tomorrow after market close. Here’s what you need to know. Inspire Medical Systems beat analysts ...
DOJ investigating Golden Valley-based Inspire’s marketing of sleep apnea device
The promotion and reimbursement practices for the medtech company’s implantable CPAP alternative are under scrutiny.